Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      GREENBROOK TMS REPORTS THIRD QUARTER OPERATIONAL AND FINANCIAL RESULTS


      News provided by

      Greenbrook TMS Inc.

      Nov 08, 2023, 18:29 ET

      Share this article

      Share this article


      TORONTO, Nov. 8, 2023 /PRNewswire/ - Greenbrook TMS Inc. (NASDAQ: GBNH) ("Greenbrook" or the "Company") today announced its third quarter 2023 ("Q3 2023") operational and financial results. All values in this news release are in United States dollars, unless otherwise stated.

      THIRD QUARTER 2023 OPERATIONAL AND FINANCIAL HIGHLIGHTS

      • Quarterly revenue decreased by 13% to $18.0 million, down $2.8 million as compared to the third quarter of 2022 ("Q3 2022") despite the closure of 53 treatment centers ("Treatment Centers") in connection with the Company's previously-announced comprehensive restructuring plan (the "Restructuring Plan") (approximately 29% of active Treatment Centers as at Q3 2022).
      • For the nine-month period ended September 30, 2023 ("YTD 2023") revenue increased by 17% to $56.3 million, up $8.3 million compared to the nine-month period ended September 30, 2022 ("YTD 2022") predominately due to the acquisition of Success TMS.
      • Quarterly revenue remained resilient at approximately 86% of the total quarterly revenue achieved in the fourth quarter of 2022 ("Q4 2022"), despite the closure of 53 Treatment Centers in connection with the Restructuring Plan and a significantly reduced marketing spend (marketing spend in Q3 2023 represented 10% of marketing spend in Q4 2022).
      • As a result of the Restructuring Plan, the Company has eliminated approximately $23 million of annualized costs from the business to date achieving its previously-announced cost savings target of between $22 to $25 million.
      • Loss for the period and comprehensive loss decreased by 24% in Q3 2023 to $12.7 million, down $4.1 million as compared to Q3 2022 and increased by 7% to $34.4 million during YTD 2023, up $2.3 million as compared to YTD 2022.
      • The Company continued its roll-out of its Spravato® (esketamine nasal spray) offering at select treatment centers to diversify its offering to patients, including our first Spravato® "buy & bill" program which will allow us to further enhance our access to patients in specific markets that require this program offering compared to our current "administer and observe" programs. The Company has expanded its Spravato® offering to 56 treatment centers to date. We expect to have 70-80 Treatment Centers offering Spravato® through an accelerated roll-out by the end of fiscal 2023.
      • The Company began a pilot program to roll-out the facilitation of medication management at select Treatment Centers. We believe this program will allow us to reach patients earlier in their treatment journey, develop an internal patient pipeline for transcranial magnetic stimulation ("TMS") and Spravato® treatments, while also further optimizing marketing costs.

      Bill Leonard, President and Chief Executive Officer of Greenbrook, commented:

      "Our business has shown remarkable resilience in spite of the challenges we've been faced with this year. Our commitment to the execution of the Restructuring Plan continued to yield positive results in Q3 2023, including our third consecutive quarter of regional operating income. The Company is in the final phases of the Restructuring Plan and anticipates that the reductions made to the business cost structure will solidify our path to profitability once we are able to resume investment in activities to support our revenue growth. We are excited to continue our roll-out of new treatment modalities, including our previously-announced medication management pilot and our newly-introduced Spravato® "buy & bill" program, which will complement our current "administer and observe" programs, allowing us to further enhance our access to patients. We believe that mental health remains a key focus in the United States and the unmet demand for treatment remains at an all-time high. We continue to offer innovative solutions for this unmet need and our leadership position and nationwide footprint continues to serve as a valuable platform to bring the needed help to patients struggling with depression."

      SELECTED THIRD QUARTER FINANCIAL AND OPERATING RESULTS (1)

      Selected Financial Results

      (US$) (unaudited)

      Q3 2023


       Q3 2022


      YTD 2023


      YTD 2022

      Total revenue

      18,035,308


      20,752,105


      56,290,158


      48,027,560

      Regional operating income (loss)

      522,925


      (849,472)


      1,488,978


      (1,958,596)

      Loss before income taxes

      (12,748,058)


      (16,783,316)


      (34,353,037)


      (32,140,803)

      Loss for the period and comprehensive loss

      (12,748,058)


      (16,783,316)


      (34,353,037)


      (32,140,803)

      Loss attributable to the common shareholders of Greenbrook

      (12,688,653)


      (16,361,426)


      (34,180,529)


      (31,547,258)

      Net loss per share (basic and diluted)

      (0.30)


      (0.59)


      (0.90)


      (1.49)

      ________
      Note:

      (1)     Please note that additional selected consolidated financial information can be found at the end of this press release.

      Selected Operating Results


      As at September 30,


      As at December 31,

      (unaudited)

      2023


      2022


      2022

      Number of active Treatment Centers(1)

      130


      183


      183

      Number of Treatment Centers-in-development(2)

      –


      1


      –

      Total Treatment Centers

      130


      184


      183

      Number of management regions

      17


      18


      18

      Number of TMS Devices installed

      261


      338


      345

      Number of regional personnel

      401


      501


      495

      Number of shared-services / corporate personnel(3)

      91


      143


      134

      Number of providers(4)

      207


      208


      225

      Number of consultations performed(5)

      26,233


      16,616


      27,831

      Number of patient starts(5)

      8,047


      6,474


      9,253

      Number of Treatments performed(5)

      253,876


      216,151


      312,940

      Average revenue per Treatment(5)

      $222


      $222


      $221

      ________
      Notes:

      (1)

      Active Treatment Centers represent Treatment Centers that have performed billable treatment services during the applicable period.

      (2)

      Treatment Centers-in-development represents Treatment Centers that have committed to a space lease agreement and the development process is substantially complete.

      (3)

      Shared-services / corporate personnel is disclosed on a full-time equivalent basis. The Company utilizes part-time staff and consultants as a means of managing costs.

      (4)

      Number of providers represents clinician partners that are involved in the provision of treatment services from our Treatment Centers.

      (5)

      Figure calculated for the applicable year or period ended.

      For more information, please refer to the Management's Discussion & Analysis of Financial Condition and Results of Operations (the "Q3 2023 MD&A") and the unaudited condensed interim consolidated financial statements of the Company for the three and nine months ended September 30, 2023 and 2022. These documents will be available on the Company's website at www.greenbrooktms.com, under the Company's SEDAR+ profile at www.sedarplus.com and under the Company's EDGAR profile at www.sec.gov.

      CONFERENCE CALL AND WEBCAST

      Third Quarter Conference Call Details:

      Bill Leonard, President and Chief Executive Officer, and Peter Willett, Interim Chief Financial Officer, will host a conference call at 12:00 p.m. (Eastern Time) on November 9, 2023 to discuss the financial results for Q3 2023.

      Toll Free North America: 1-888-886-7786

      Toronto: 416-764-8658

      Webcast:

      For more information or to listen to the call via webcast, please visit:
      www.greenbrooktms.com/investors/events.htm

      For those that plan on accessing the conference call or webcast, please allow ample time prior to the call time.

      Conference Call Replay:

      Following the live call, a replay will be available on the Investor Relations section of the Company's website and www.greenbrooktms.com/investors/events.htm

      About Greenbrook TMS Inc.

      Operating through 130 Company-operated Treatment Centers, Greenbrook is a leading provider of TMS and Spravato® (esketamine nasal spray), FDA-cleared, non-invasive therapies for the treatment of Major Depressive Disorder ("MDD") and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Spravato® is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. Greenbrook has provided more than 1.3 million treatments to over 40,000 patients struggling with depression.

      Cautionary Note Regarding Forward-Looking Information

      Certain information in this press release, including, but not limited to, information with respect to the Company's future financial or operating performance, the Company's expectations regarding the impact of the Restructuring Plan on our business, and the continued roll-out of the Spravato® and medication management offering at additional Treatment Centers and its potential to enhance profit margins and diversify total revenue, constitute forward-looking information within the meaning of applicable securities laws in Canada and the United States, including the United States Private Securities Litigation Reform Act of 1995. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events.

      Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this press release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements, including, without limitation: macroeconomic factors such as inflation and recessionary conditions, substantial doubt regarding the Company's ability to continue as a going concern due to recurring losses from operations; inability to increase cash flow and/or raise sufficient capital to support the Company's operating activities and fund its cash obligations, repay indebtedness and satisfy the Company's working capital needs and debt obligations; prolonged decline in the price of the common shares of the Company ("Common Shares") reducing the Company's ability to raise capital; inability to satisfy debt covenants under the Company's credit facility and the potential acceleration of indebtedness; including as a result of an unfavorable decision in respect of the litigation with Benjamin Klein; risks related to the ability to continue to negotiate amendments to the Company's credit facility to prevent a default; risks relating to the Company's ability to deliver and execute on the Restructuring Plan and  the possible failure to complete the Restructuring Plan on terms acceptable to the Company or its suppliers (including Neuronetics Inc.), or at all; risks relating to maintaining an active, liquid and orderly trading market for Common Shares as a result of the Company's potential inability to regain compliance with the Nasdaq Stock Market's listing rules; risks relating to the Company's ability to realize expected cost-savings and other anticipated benefits from the Restructuring Plan; risks related to the Company's negative cash flows, liquidity and its ability to secure additional financing; increases in indebtedness levels causing a reduction in financial flexibility; inability to achieve or sustain profitability in the future; inability to secure additional financing to fund losses from operations and satisfy the Company's debt obligations; risks relating to strategic alternatives, including restructuring or refinancing of the Company's debt, seeking additional debt or equity capital, reducing or delaying the Company's business activities and strategic initiatives, or selling assets, other strategic transactions and/or other measures, including obtaining bankruptcy protection, and the terms, value and timing of any transaction resulting from that process; claims made by or against the Company, which may be resolved unfavorably to us; risks relating to the Company's dependence on Neuronetics Inc. as its exclusive supplier of TMS devices. Additional risks and uncertainties are discussed in the Company's materials filed with the Canadian securities regulatory authorities and the United States Securities and Exchange Commission from time to time, available at www.sedarplus.com and www.sec.gov, respectively. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

      Selected Consolidated Financial Information

      (US$) (unaudited)

      Q3 2023


      Q3 2022


      YTD 2023


      YTD 2022

      Total revenue

      18,035,308


      20,752,105


      56,290,158


      48,027,560









      Direct center and patient care costs

      10,840,776


      10,207,404


      33,785,962


      25,193,562

      Regional employee compensation

      4,356,592


      5,081,645


      13,129,558


      11,918,622

      Regional marketing expenses

      407,538


      3,176,159


      1,224,139


      6,581,059

      Depreciation

      1,907,477


      3,136,369


      6,661,521


      6,292,913

      Total direct center and regional costs

      17,512,383


      21,601,577


      54,801,180


      49,986,156

      Regional operating income (loss)

      522,925


      (849,472)


      1,488,978


      (1,958,596)

      Center development costs

      137,770


      215,954


      355,832


      562,108

      Corporate employee compensation

      3,629,623


      5,156,259


      11,880,351


      12,211,803

      Corporate marketing expenses

      52,237


      169,653


      83,504


      394,223

      Other corporate, general and administrative expenses

      1,954,017


      4,303,486


      7,311,213


      7,759,607

      Share-based compensation

      14,740


      2,762


      591,470


      315,966

      Amortization

      343,253


      570,648


      1,029,758


      985,648

      Interest expense

      3,992,801


      3,183,165


      11,443,446


      5,633,165

      Interest income

      (64)


      –


      (165)


      (12,230)

      Loss (gain) on extinguishment of loans

      (34,510)


      2,331,917


      (34,510)


      2,331,917

      Loss on device contract termination

      3,181,116


      –


      3,181,116


      –

      Loss before income taxes

      (12,748,058)


      (16,783,316)


      (34,353,037)


      (32,140,803)

      Income tax expense

      –


      –


      –


      –

      Loss for the period and comprehensive loss

      (12,748,058)


      (16,783,316)


      (34,353,037)


      (32,140,803)

      Loss attributable to non-controlling interest

      (59,405)


      (421,890)


      (172,508)


      (593,545)

      Loss attributable to the common shareholders of Greenbrook

      (12,688,653)


      (16,361,426)


      (34,180,529)


      (31,547,258)

      Net loss per share (basic and diluted) 

      (0.30)


      (0.59)


      (0.90)


      (1.49)


      Q3 2023


      Q2 2023

      Q1 2023


      Q4 2022


      Q3 2022


      Q2 2022


      Q1 2022


      Q4 2021

      (US$) (unaudited)















      Revenue

      18,035,308


      18,346,799

      19,908,051


      21,076,886


      20,752,105


      14,210,309


      13,065,146


      14,047,452

      Regional operating income (loss)

      522,925


      237,003

      729,050


      (141,846)


      (849,472)


      (71,075)


      (1,038,049)


      43,741

      Net loss attributable to common shareholders of Greenbrook

      (12,688,653)


      (12,259,994)

      (9,231,882)


      (30,179,216)


      (16,361,426)


      (7,347,849)


      (7,837,983)


      (6,831,859)

      Net loss per share – Basic

      (0.30)


      (0.30)

      (0.30)


      (1.22)


      (0.59)


      (0.41)


      (0.44)


      (0.34)

      Net loss per share – Diluted

      (0.30)


      (0.30)

      (0.30)


      (1.22)


      (0.59)


      (0.41)


      (0.44)


      (0.34)

      SOURCE Greenbrook TMS Inc.

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.